The FDA’s Oncologic Drugs Advisory Committee (ODAC) has unanimously called for a revamp of perioperative clinical trial designs in resectable non-small cell lung cancer (NSCLC) to include assessment of the contribution of each treatment phase.
Argenx `s Biologic Vyvgart (Efgartigimod) Receives Suppl Approvals in US
July 18, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
Johnson & Johnson has presented phase 3 data on nipocalimab in generalized myasthenia gravis (gMG), providing a look at how its $6.5 billion prospect matches up to the approved FcRn rivals from argenx and UCB.
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of...
Argenx snares 2nd US nod for Vyvgart Hytrulo
Argenx Bv Biologic Efgartigimod Alfa And Hyaluronidase-Qvfc Receives Approval in US
R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to Phase 3 development Next...
Plus, news about Y-Biologics, Navigator Medicines, Spur Therapeutics, Disc Medicine and Mereo BioPharma: